Collegium Pharmaceutical (COLL) Scheduled to Post Quarterly Earnings on Thursday

Collegium Pharmaceutical (NASDAQ:COLL) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of $1.37 per share for the quarter. Collegium Pharmaceutical has set its FY 2024 guidance at EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.25. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. The company had revenue of $149.75 million for the quarter, compared to analyst estimates of $147.66 million. On average, analysts expect Collegium Pharmaceutical to post $6 EPS for the current fiscal year and $6 EPS for the next fiscal year.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $37.30 on Wednesday. The company has a debt-to-equity ratio of 2.48, a quick ratio of 1.10 and a current ratio of 1.17. Collegium Pharmaceutical has a fifty-two week low of $20.83 and a fifty-two week high of $40.95. The firm has a market capitalization of $1.22 billion, a PE ratio of 31.61 and a beta of 1.06. The stock’s 50-day simple moving average is $37.58 and its 200-day simple moving average is $32.13.

Analyst Ratings Changes

Several equities analysts have issued reports on COLL shares. StockNews.com cut shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Piper Sandler reissued an “overweight” rating and issued a $39.00 target price (up previously from $37.00) on shares of Collegium Pharmaceutical in a research note on Friday, February 23rd. Needham & Company LLC reiterated a “buy” rating and issued a $40.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Finally, Truist Financial raised their target price on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a report on Monday, February 26th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $39.00.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.